Search

Author/Creator Kushwaha, R.

1. AB801 is a potent and selective AXL inhibitor that demonstrates significant anti-tumor activity in combination with standard of care therapeutics. (October 2022)

Authors:
Paprcka, S.; Sridhar, S.; Goshayeshi, A.; Park, E.; Liu, S.; Flores, R.; Rocha, L.; Miles, D.; Lamani, M.; Cho, S.; Wang, N.; Guan, Y.; Chandrasekar, S.; Kushwaha, R.; Jafri, S.; Kaplan, A.; Stagnaro, E.; Seitz, L.; Kline, J.; Fernandez-Salas, E.
Journal:
European journal of cancer
Issue:
Volume 174(2022)Supplement 1
Page Start:
S110
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. Issue 1 (January 2021)

Authors:
Fernandez, Laura M; São Julião, Guilherme P; Figueiredo, Nuno L; Beets, Geerard L; van der Valk, Maxime J M; Bahadoer, Renu R; Hilling, Denise E; Meershoek-Klein Kranenbarg, Elma; Roodvoets, Annet G H; Renehan, Andrew G; van de Velde, Cornelis J H; Habr-Gama, Angelita; Perez, Rodrigo O; Abdelraze...
Journal:
Lancet oncology
Issue:
Volume 22:Issue 1(2021)
Page Start:
43
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗